Results of a phase II trial of azacitidine (AZA) with or without epoetin beta (EPO) in lower-risk MDS.
Claude Gardin
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Research Funding - Celgene
Sylvain Thépot
Honoraria - Celgene
Odile Beyne-Rauzy
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Research Funding - Celgene
Other Remuneration - Celgene
Thomas Prébet
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Research Funding - Celgene
Sophie Park
Research Funding - Novartis
Aspasia Stamatoulas
No relevant relationships to disclose
Agnes Guerci-Bresler
No relevant relationships to disclose
Stephane Cheze
No relevant relationships to disclose
Gerard Tertian
No relevant relationships to disclose
B Choufi
No relevant relationships to disclose
Laurence Legros
No relevant relationships to disclose
jean Noel Bastie
No relevant relationships to disclose
Jacques Delaunay
No relevant relationships to disclose
Eric Wattel
No relevant relationships to disclose
Francois Dreyfus
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Research Funding - Celgene
Other Remuneration - Celgene
Norbert Vey
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Research Funding - Celgene
Other Remuneration - Celgene
Simone Boehrer
Research Funding - Celgene
Pierre Fenaux
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Research Funding - Celgene
Expert Testimony - Celgene
Other Remuneration - Celgene